Best products for post-acne marks

Systematic review: ALL 14 clinical studies found thiamidol to provide statistically significant improvements to hyperpigmentation conditions; consistent efficacy across facial hyperpigmentation melasma PIH and UV induced hyperpigmentation indications.

Randomized controlled trial (n=48, 24 weeks): Clinical photography and MASI improved significantly with Thiamidol vs baseline p<0.001 and vs vehicle p<0.001 to 0.043 at all time points up to treatment end; well tolerated; regression phase showed MASI still significantly lower than baseline but similar for treatment and vehicle groups indicating maintenance treatment required.

Randomized controlled trial: Serum containing HA plus arctiin plus thiamidol reduced both age spots and wrinkles and increased elasticity of mature skin.

Randomized controlled trial: Suction blister PIH sites treated with thiamidol significantly lighter than control at 2 weeks and improved throughout 12 weeks; acne related PIH vehicle controlled RCT demonstrated significant thiamidol efficacy; 12 week three product thiamidol observational study confirmed efficacy.

In-vitro/mechanistic study: Thiamidol isobutylamido thiazolyl resorcinol identified as most potent inhibitor of human tyrosinase from 50000 compounds screened; thiamidol IC50 1.1 uM on human tyrosinase vs hydroquinone IC50 greater than 4000 uM vs alpha arbutin IC50 in millimolar range vs kojic acid IC50 greater than 400 uM; thiamidol IC50 108 uM on mushroom tyrosinase demonstrating greater than 98x selectivity for human vs mushroom tyrosinase; melanocyte culture IC50 0.9 uM reversibly inhibits melanin production vs hydroquinone 16.3 uM irreversible inhibition via cytotoxicity.

Review: Modern 2024 review consolidating thiamidol efficacy safety tolerability evidence; dermatology specialist perspective on thiamidol clinical utility.

Review: Recent 2025 dermatology specialist review positioning thiamidol as breakthrough innovation in hyperpigmentation treatment; discusses Kligman alternative combination with tretinoin and dexamethasone.

Review: 2024 European dermatology review consolidating thiamidol evidence base and clinical applications.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Meta-analysis (n=667): Early systematic review demonstrating MASI decrease of 1.60 95% CI 1.20 2.00 p=0.001 with TXA and additional 0.94 decrease when added to routine treatment; established evidence base for TXA in melasma.

Meta-analysis: Oral TXA efficacy demonstrated in Asian skin including low dose 500 mg daily over 8 to 12 weeks; safety profile established.

Meta-analysis: Demonstrates significant MASI mMASI reduction at 4 8 12 16 weeks regardless of route; oral route most robust effect vs routine treatment.

Meta-analysis: PIVOTAL network meta analysis establishing optimal oral dose as 250 mg three times daily 750 mg total daily for 12 weeks with 250 mg twice daily acceptable alternative.

Meta-analysis: Comprehensive 2024 meta analysis demonstrating oral TXA SMD 2.39 at 12 weeks 95% CI 1.42 3.35 p=0.00001; establishes oral route as primary evidence based option.

Double-blind split-face RCT (n=23, 21 completed): topical 5% tranexamic acid gel vs vehicle twice daily for 12 weeks in epidermal melasma; MASI fell on both sides but TXA was not superior to vehicle (p>0.05), and TXA caused significant erythema, indicating no benefit over vehicle.

Randomized, double-blind, placebo-controlled trial in moderate-to-severe melasma: oral tranexamic acid 250 mg twice daily significantly reduced modified MASI versus placebo over 3 months; pigmentation partially returned after discontinuation; treatment was well tolerated with no serious adverse events.

Uncontrolled clinical study (n=74): oral tranexamic acid 250 mg twice daily for 6 months for melasma; about 65% of patients achieved good-to-excellent improvement (excellent 10.8%, good 54%), with fair in ~31% and poor in ~4%; supports oral TXA efficacy, though there was no control group.

In a 12-week double-blind split-face trial of 50 Iranian women, topical 3% tranexamic acid and 3% hydroquinone plus 0.01% dexamethasone both significantly reduced MASI scores with no significant difference between them. Tranexamic acid caused significantly fewer side effects, supporting it as an effective, safer melasma treatment.

Randomized controlled trial: Demonstrates topical liposomal TXA 5% comparable efficacy to hydroquinone 2% for melasma.

Meta-analysis (n=667): Early systematic review demonstrating MASI decrease of 1.60 95% CI 1.20 2.00 p=0.001 with TXA and additional 0.94 decrease when added to routine treatment; established evidence base for TXA in melasma.

Meta-analysis: Oral TXA efficacy demonstrated in Asian skin including low dose 500 mg daily over 8 to 12 weeks; safety profile established.

Meta-analysis: Demonstrates significant MASI mMASI reduction at 4 8 12 16 weeks regardless of route; oral route most robust effect vs routine treatment.

Meta-analysis: PIVOTAL network meta analysis establishing optimal oral dose as 250 mg three times daily 750 mg total daily for 12 weeks with 250 mg twice daily acceptable alternative.

Meta-analysis: Comprehensive 2024 meta analysis demonstrating oral TXA SMD 2.39 at 12 weeks 95% CI 1.42 3.35 p=0.00001; establishes oral route as primary evidence based option.

Double-blind split-face RCT (n=23, 21 completed): topical 5% tranexamic acid gel vs vehicle twice daily for 12 weeks in epidermal melasma; MASI fell on both sides but TXA was not superior to vehicle (p>0.05), and TXA caused significant erythema, indicating no benefit over vehicle.

Randomized, double-blind, placebo-controlled trial in moderate-to-severe melasma: oral tranexamic acid 250 mg twice daily significantly reduced modified MASI versus placebo over 3 months; pigmentation partially returned after discontinuation; treatment was well tolerated with no serious adverse events.

Uncontrolled clinical study (n=74): oral tranexamic acid 250 mg twice daily for 6 months for melasma; about 65% of patients achieved good-to-excellent improvement (excellent 10.8%, good 54%), with fair in ~31% and poor in ~4%; supports oral TXA efficacy, though there was no control group.

In a 12-week double-blind split-face trial of 50 Iranian women, topical 3% tranexamic acid and 3% hydroquinone plus 0.01% dexamethasone both significantly reduced MASI scores with no significant difference between them. Tranexamic acid caused significantly fewer side effects, supporting it as an effective, safer melasma treatment.

Randomized controlled trial: Demonstrates topical liposomal TXA 5% comparable efficacy to hydroquinone 2% for melasma.

Meta-analysis (n=667): Early systematic review demonstrating MASI decrease of 1.60 95% CI 1.20 2.00 p=0.001 with TXA and additional 0.94 decrease when added to routine treatment; established evidence base for TXA in melasma.

Meta-analysis: Oral TXA efficacy demonstrated in Asian skin including low dose 500 mg daily over 8 to 12 weeks; safety profile established.

Meta-analysis: Demonstrates significant MASI mMASI reduction at 4 8 12 16 weeks regardless of route; oral route most robust effect vs routine treatment.

Meta-analysis: PIVOTAL network meta analysis establishing optimal oral dose as 250 mg three times daily 750 mg total daily for 12 weeks with 250 mg twice daily acceptable alternative.

Meta-analysis: Comprehensive 2024 meta analysis demonstrating oral TXA SMD 2.39 at 12 weeks 95% CI 1.42 3.35 p=0.00001; establishes oral route as primary evidence based option.

Double-blind split-face RCT (n=23, 21 completed): topical 5% tranexamic acid gel vs vehicle twice daily for 12 weeks in epidermal melasma; MASI fell on both sides but TXA was not superior to vehicle (p>0.05), and TXA caused significant erythema, indicating no benefit over vehicle.

Randomized, double-blind, placebo-controlled trial in moderate-to-severe melasma: oral tranexamic acid 250 mg twice daily significantly reduced modified MASI versus placebo over 3 months; pigmentation partially returned after discontinuation; treatment was well tolerated with no serious adverse events.

Uncontrolled clinical study (n=74): oral tranexamic acid 250 mg twice daily for 6 months for melasma; about 65% of patients achieved good-to-excellent improvement (excellent 10.8%, good 54%), with fair in ~31% and poor in ~4%; supports oral TXA efficacy, though there was no control group.

In a 12-week double-blind split-face trial of 50 Iranian women, topical 3% tranexamic acid and 3% hydroquinone plus 0.01% dexamethasone both significantly reduced MASI scores with no significant difference between them. Tranexamic acid caused significantly fewer side effects, supporting it as an effective, safer melasma treatment.

Randomized controlled trial: Demonstrates topical liposomal TXA 5% comparable efficacy to hydroquinone 2% for melasma.

Meta-analysis (n=667): Early systematic review demonstrating MASI decrease of 1.60 95% CI 1.20 2.00 p=0.001 with TXA and additional 0.94 decrease when added to routine treatment; established evidence base for TXA in melasma.

Meta-analysis: Oral TXA efficacy demonstrated in Asian skin including low dose 500 mg daily over 8 to 12 weeks; safety profile established.

Meta-analysis: Demonstrates significant MASI mMASI reduction at 4 8 12 16 weeks regardless of route; oral route most robust effect vs routine treatment.

Meta-analysis: PIVOTAL network meta analysis establishing optimal oral dose as 250 mg three times daily 750 mg total daily for 12 weeks with 250 mg twice daily acceptable alternative.

Meta-analysis: Comprehensive 2024 meta analysis demonstrating oral TXA SMD 2.39 at 12 weeks 95% CI 1.42 3.35 p=0.00001; establishes oral route as primary evidence based option.

Double-blind split-face RCT (n=23, 21 completed): topical 5% tranexamic acid gel vs vehicle twice daily for 12 weeks in epidermal melasma; MASI fell on both sides but TXA was not superior to vehicle (p>0.05), and TXA caused significant erythema, indicating no benefit over vehicle.

Randomized, double-blind, placebo-controlled trial in moderate-to-severe melasma: oral tranexamic acid 250 mg twice daily significantly reduced modified MASI versus placebo over 3 months; pigmentation partially returned after discontinuation; treatment was well tolerated with no serious adverse events.

Uncontrolled clinical study (n=74): oral tranexamic acid 250 mg twice daily for 6 months for melasma; about 65% of patients achieved good-to-excellent improvement (excellent 10.8%, good 54%), with fair in ~31% and poor in ~4%; supports oral TXA efficacy, though there was no control group.

In a 12-week double-blind split-face trial of 50 Iranian women, topical 3% tranexamic acid and 3% hydroquinone plus 0.01% dexamethasone both significantly reduced MASI scores with no significant difference between them. Tranexamic acid caused significantly fewer side effects, supporting it as an effective, safer melasma treatment.

Randomized controlled trial: Demonstrates topical liposomal TXA 5% comparable efficacy to hydroquinone 2% for melasma.

Comprehensive review of arbutin mechanisms: alpha-arbutin competitively inhibits tyrosinase by binding the active site without melanocyte cytotoxicity; also exhibits antioxidant properties; safer alternative to hydroquinone as it does not form toxic benzoquinone metabolites

Review of PIH management in skin of color: arbutin is recommended as a well-tolerated depigmenting agent for acne-related PIH in Fitzpatrick III-VI; lower irritation risk than hydroquinone reduces the chance of treatment-induced inflammation (which would worsen PIH); optimal at 1-2% concentration in combination with sunscreen and gentle retinoids

Randomized, open-label study (n=30) in melasma comparing topical gels of arbutin, synthetic ellagic acid, and plant-derived ellagic acid; all three significantly reduced melanin levels, with arbutin producing a significant response in all 10 treated patients (p=0.05). No hydroquinone comparator and no PIH endpoint.

Randomized controlled trial (n=30, 12 weeks): AAK comparable efficacy to TCC for melasma similar melanin index and mMASI score reductions; TCC had significantly higher PGA improvement week 4 p=0.002 week 8 p<0.01 week 12 p=0.032 but comparable objective measures and TCC showed higher recurrence severity at week 16 follow up.

Clinical study (n=30, 4 weeks): Combination serum comparable to hydroquinone 4% for skin brightness L star and pigmentation intensity improvement at 4 weeks.

Clinical study (2 weeks): Arbutin reduced UVR induced hyperpigmentation by 43.5% vs vehicle aleosin by 34% combination by 63.3%.

Biochemical study: both α- and β-arbutin inhibit tyrosinase activity from mushroom and mouse (B16) melanoma; arbutin competitively inhibits tyrosinase, the basis for its melanin-synthesis-suppressing, skin-lightening effect.

Alpha-arbutin inhibited melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model via inhibition of tyrosinase activity, supporting alpha-arbutin as an effective skin-lightening cosmetic ingredient.

In-vitro kinetic and molecular-docking study: alpha- and beta-arbutin act as alternative substrates of tyrosinase, producing apparent competitive inhibition versus L-tyrosine/L-DOPA rather than acting as pure inhibitors; both are hydroxylated at the ortho position, with beta-arbutin showing higher enzyme affinity (lower KM) than alpha-arbutin.

In-vitro/mechanistic study: PIVOTAL comprehensive review consolidating alpha arbutin mechanism evidence and clinical applications; documents 10 fold potency advantage over beta arbutin; consolidates skin lightening mechanism plus additional therapeutic applications cancer diabetes neurodegenerative.

Comprehensive review of arbutin mechanisms: alpha-arbutin competitively inhibits tyrosinase by binding the active site without melanocyte cytotoxicity; also exhibits antioxidant properties; safer alternative to hydroquinone as it does not form toxic benzoquinone metabolites

Review of PIH management in skin of color: arbutin is recommended as a well-tolerated depigmenting agent for acne-related PIH in Fitzpatrick III-VI; lower irritation risk than hydroquinone reduces the chance of treatment-induced inflammation (which would worsen PIH); optimal at 1-2% concentration in combination with sunscreen and gentle retinoids

Randomized, open-label study (n=30) in melasma comparing topical gels of arbutin, synthetic ellagic acid, and plant-derived ellagic acid; all three significantly reduced melanin levels, with arbutin producing a significant response in all 10 treated patients (p=0.05). No hydroquinone comparator and no PIH endpoint.

Randomized controlled trial (n=30, 12 weeks): AAK comparable efficacy to TCC for melasma similar melanin index and mMASI score reductions; TCC had significantly higher PGA improvement week 4 p=0.002 week 8 p<0.01 week 12 p=0.032 but comparable objective measures and TCC showed higher recurrence severity at week 16 follow up.

Clinical study (n=30, 4 weeks): Combination serum comparable to hydroquinone 4% for skin brightness L star and pigmentation intensity improvement at 4 weeks.

Clinical study (2 weeks): Arbutin reduced UVR induced hyperpigmentation by 43.5% vs vehicle aleosin by 34% combination by 63.3%.

Biochemical study: both α- and β-arbutin inhibit tyrosinase activity from mushroom and mouse (B16) melanoma; arbutin competitively inhibits tyrosinase, the basis for its melanin-synthesis-suppressing, skin-lightening effect.

Alpha-arbutin inhibited melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model via inhibition of tyrosinase activity, supporting alpha-arbutin as an effective skin-lightening cosmetic ingredient.

In-vitro kinetic and molecular-docking study: alpha- and beta-arbutin act as alternative substrates of tyrosinase, producing apparent competitive inhibition versus L-tyrosine/L-DOPA rather than acting as pure inhibitors; both are hydroxylated at the ortho position, with beta-arbutin showing higher enzyme affinity (lower KM) than alpha-arbutin.

In-vitro/mechanistic study: PIVOTAL comprehensive review consolidating alpha arbutin mechanism evidence and clinical applications; documents 10 fold potency advantage over beta arbutin; consolidates skin lightening mechanism plus additional therapeutic applications cancer diabetes neurodegenerative.

Comprehensive review of arbutin mechanisms: alpha-arbutin competitively inhibits tyrosinase by binding the active site without melanocyte cytotoxicity; also exhibits antioxidant properties; safer alternative to hydroquinone as it does not form toxic benzoquinone metabolites

Review of PIH management in skin of color: arbutin is recommended as a well-tolerated depigmenting agent for acne-related PIH in Fitzpatrick III-VI; lower irritation risk than hydroquinone reduces the chance of treatment-induced inflammation (which would worsen PIH); optimal at 1-2% concentration in combination with sunscreen and gentle retinoids

Randomized, open-label study (n=30) in melasma comparing topical gels of arbutin, synthetic ellagic acid, and plant-derived ellagic acid; all three significantly reduced melanin levels, with arbutin producing a significant response in all 10 treated patients (p=0.05). No hydroquinone comparator and no PIH endpoint.

Randomized controlled trial (n=30, 12 weeks): AAK comparable efficacy to TCC for melasma similar melanin index and mMASI score reductions; TCC had significantly higher PGA improvement week 4 p=0.002 week 8 p<0.01 week 12 p=0.032 but comparable objective measures and TCC showed higher recurrence severity at week 16 follow up.

Clinical study (n=30, 4 weeks): Combination serum comparable to hydroquinone 4% for skin brightness L star and pigmentation intensity improvement at 4 weeks.

Clinical study (2 weeks): Arbutin reduced UVR induced hyperpigmentation by 43.5% vs vehicle aleosin by 34% combination by 63.3%.

Biochemical study: both α- and β-arbutin inhibit tyrosinase activity from mushroom and mouse (B16) melanoma; arbutin competitively inhibits tyrosinase, the basis for its melanin-synthesis-suppressing, skin-lightening effect.

Alpha-arbutin inhibited melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model via inhibition of tyrosinase activity, supporting alpha-arbutin as an effective skin-lightening cosmetic ingredient.

In-vitro kinetic and molecular-docking study: alpha- and beta-arbutin act as alternative substrates of tyrosinase, producing apparent competitive inhibition versus L-tyrosine/L-DOPA rather than acting as pure inhibitors; both are hydroxylated at the ortho position, with beta-arbutin showing higher enzyme affinity (lower KM) than alpha-arbutin.

In-vitro/mechanistic study: PIVOTAL comprehensive review consolidating alpha arbutin mechanism evidence and clinical applications; documents 10 fold potency advantage over beta arbutin; consolidates skin lightening mechanism plus additional therapeutic applications cancer diabetes neurodegenerative.

Comprehensive review of arbutin mechanisms: alpha-arbutin competitively inhibits tyrosinase by binding the active site without melanocyte cytotoxicity; also exhibits antioxidant properties; safer alternative to hydroquinone as it does not form toxic benzoquinone metabolites

Review of PIH management in skin of color: arbutin is recommended as a well-tolerated depigmenting agent for acne-related PIH in Fitzpatrick III-VI; lower irritation risk than hydroquinone reduces the chance of treatment-induced inflammation (which would worsen PIH); optimal at 1-2% concentration in combination with sunscreen and gentle retinoids

Randomized, open-label study (n=30) in melasma comparing topical gels of arbutin, synthetic ellagic acid, and plant-derived ellagic acid; all three significantly reduced melanin levels, with arbutin producing a significant response in all 10 treated patients (p=0.05). No hydroquinone comparator and no PIH endpoint.

Randomized controlled trial (n=30, 12 weeks): AAK comparable efficacy to TCC for melasma similar melanin index and mMASI score reductions; TCC had significantly higher PGA improvement week 4 p=0.002 week 8 p<0.01 week 12 p=0.032 but comparable objective measures and TCC showed higher recurrence severity at week 16 follow up.

Clinical study (n=30, 4 weeks): Combination serum comparable to hydroquinone 4% for skin brightness L star and pigmentation intensity improvement at 4 weeks.

Clinical study (2 weeks): Arbutin reduced UVR induced hyperpigmentation by 43.5% vs vehicle aleosin by 34% combination by 63.3%.

Biochemical study: both α- and β-arbutin inhibit tyrosinase activity from mushroom and mouse (B16) melanoma; arbutin competitively inhibits tyrosinase, the basis for its melanin-synthesis-suppressing, skin-lightening effect.

Alpha-arbutin inhibited melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model via inhibition of tyrosinase activity, supporting alpha-arbutin as an effective skin-lightening cosmetic ingredient.

In-vitro kinetic and molecular-docking study: alpha- and beta-arbutin act as alternative substrates of tyrosinase, producing apparent competitive inhibition versus L-tyrosine/L-DOPA rather than acting as pure inhibitors; both are hydroxylated at the ortho position, with beta-arbutin showing higher enzyme affinity (lower KM) than alpha-arbutin.

In-vitro/mechanistic study: PIVOTAL comprehensive review consolidating alpha arbutin mechanism evidence and clinical applications; documents 10 fold potency advantage over beta arbutin; consolidates skin lightening mechanism plus additional therapeutic applications cancer diabetes neurodegenerative.

Azelaic acid 20% cream was superior to hydroquinone 2% cream for facial melasma in dark-skinned patients, with 73% achieving good-to-excellent results versus 19%. Both treatments caused transient mild-to-moderate irritation.

Systematic review: Consolidated rosacea evidence confirming efficacy.

Randomized controlled trial: Dioic acid azelaic derivative vs hydroquinone PIH and melasma.

In this phase 3 trial, twice-daily azelaic acid foam 15% was significantly superior to vehicle in papulopustular rosacea, achieving higher investigator global assessment success rates and greater inflammatory lesion count reduction (both P<.001). Adverse events were mainly mild-to-moderate local cutaneous reactions.

Randomized controlled trial: Acne evidence for 20% cream FDA approval basis.

Randomized controlled trial (n=664, 12 weeks): FDA approval pivotal evidence for Finacea 15% gel for papulopustular rosacea; 58 and 51% inflammatory lesion reduction vs 40 and 39% vehicle.

Azelaic acid 15% gel was superior to metronidazole 0.75% gel in reducing inflammatory lesion count (−72% vs −54%, p=0.017) and erythema in rosacea at 15 weeks; significantly more patients achieved IGA success

Large RCT (n=329): azelaic acid 20% comparable to hydroquinone 4% for melasma (65% vs 73% improvement, p=ns) with markedly fewer side effects (3% vs 26% local irritation); no ochronosis or rebound with azelaic acid

Review: Consolidated review of azelaic acne and hyperpigmentation evidence base.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.